Ceapro Inc V.CZO

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc > 20 Million Ex Cash

<< Previous

Bullboard Posts

Next >>

Comment by PBaelishhon Sep 04, 2023 2:05pm

54 Views

Post# 35618917

RE:RE:RE:20 Million Ex Cash

Who knows where Siggy iS... It still appears to be the the "Gilles Gagnon Show". Names are announced by way of press releases and we see no evidence of them.

We keep citing minimums so I had to share this thought - inference - as that is all we can do with this one-man clown show.

Apparently as has been stated by Gagnon, there are minimum quantities that Symrise, Ceapro’s only source of revenue, is contracted to purchase. He has not told us what those minimums are so we are left to infer, as each quarter plumbs a new depth, what they are.

At this point, we know the minimum is below $1,750,000 per quarter or $7,000,000 PER YEAR… at MOST.

Relative to 2022’s record year of $18,839,000 of revenue, $7,000,000 in revenue would represent a 63% drop in annual revenue.

What kind of fool puts out a press release announcing the extension of a lousy contract days before announcing one of the worst quarters… and the 3rd quarter in a row posting a loss?! Talk about rearranging the deck chairs on the Titanic.

It is actually insulting.

This odd behavior begs some questions:

What on earth made Gagnon think extending the contract was newsworthy?
What is the point of extending a lousy contract? (See minimums point above)
Why was Gilles Gagnon spending time extending a lousy contract when, MONTHS AGO, he knew revenues for Q2 were dismal?
How was this an effective use of Gilles Gagnon, CEO MBA’s time?
What is the guidance on Q3 now that we are 2/3s of the way through it?

Gilles Gagnon is an arrogant liar. After saying the same things over and over again with the only difference being timelines pushed out, that IS lying.

Chris Hitchens once said, “A good liar must have a good memory.” As Ciao pointed-out last week, Gagnon is not keeping track of his lies; he constantly regurgitates milestones, merely changing the dates to be further ou

THE BORED OF DIRECTORS

I reiterate from my last post; the board is getting free money… to the tune of $467,000 for 6 months.

$120,000 for each: